Fixing The Weak Links In The Cell Therapy Manufacturing Chain: Processes, People, And Partnerships
Source: Cytiva

The cell and gene therapy industry can move faster by shoring up its weakest links. Q&A with GE Healthcare’s Phil Vanek about how to do it.
A version of this podcast interview was originally published in Cell and Gene Therapy Insights on April 30, 2018. Vanek P. Fixing the weak links in the cell therapy manufacturing chain: processes, people and partnerships. Cell Gene Therapy Insights 2018; 4(4), 309-316. DOI: 10.18609/cgti.2018.031.
VIEW THE Q&A!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Cell & Gene? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more